All 12 girls and women with Rett syndrome given the gene therapy candidate TSHA-102 in a clinical trial gained…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Stimulating the vagus nerve, part of the autonomic nervous system that regulates involuntary functions, paired with sound tones, may support…
Fenfluramine, an add-on medication already approved for certain types of epilepsy, may also help to reduce the frequency of hard-to-treat…
MIT researchers have discovered that tiny blood vessels in the brains of people with Rett syndrome may be more…
Modulating nerve cells to boost production of the mutant form of the MeCP2 protein that causes most cases of…
While early brain structures appear to form normally in Rett syndrome, problems emerge later as brain cells grow, move,…
In Rett syndrome, certain brain cells that form before birth and mature slowly remain immature and do not develop…
Partially restoring the production of MeCP2, the protein deficient in people with Rett syndrome, reversed abnormal nerve signaling in…
The U.S. Food and Drug Administration (FDA) has approved Daybue Stix (trofinetide), a dye- and preservative-free powder formulation of…
One year of daily Daybue (trofinetide) treatment led to improvements in behaviors such as nonverbal communication, alertness, and social…